Aptorum Group News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.05.23	Pre-market Movers: CWD, HOWL, DLO, TTWO, BOOT… (RTTNews)
28.04.23	Pre-market Movers: MEGL, TOP, AGBA, KA, SIEB… (RTTNews)
27.03.23	Aptorum Group Inks Non-binding LoI And Term Sheet To Buy 100% Of URF Holding Group (RTTNews)
27.03.23	Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group (Businesswire)
03.03.23	Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma (Businesswire)
03.03.23	Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus (Businesswire)
02.03.23	Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China (Businesswire)
06.02.23	Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023 (Businesswire)
20.01.23	Aptorum Group Announces 1-for-10 Reverse Stock Split (Businesswire)
22.12.22	Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders (Businesswire)
16.12.22	Aptorum Group Announces Completion of $3 Million Convertible Note due 2023 (Businesswire)
09.12.22	Aptorum Group Announces Offering of $3 Million Convertible Note due 2023 (Businesswire)
18.11.22	Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency (Businesswire)
08.11.22	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022 (Businesswire)
15.09.22	Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong (Businesswire)
15.09.22	Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics (Businesswire)
26.08.22	Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022 (Businesswire)
17.05.22	Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022 (Businesswire)
02.05.22	Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma (Businesswire)
29.04.22	Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update (Businesswire)
25.04.22	First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted (Businesswire)
22.04.22	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report® (Businesswire)
28.01.22	Pre-market Movers: IMPP, PRVB, HOOD, ATIF, WDC… (RTTNews)
26.01.22	Pre-market Movers: GATO, XELA, NXPL, XCUR, MYNZ… (RTTNews)
25.01.22	Pre-market Movers: APM, BSFC, INPX, UPC, KAVL… (RTTNews)
24.01.22	Pre-market Movers: BTBD, RETO, KSS, BON, PT… (RTTNews)
21.01.22	Pre-market Movers: BSFC, APM, KTRA, RIOT, PIXY… (RTTNews)
09.07.21	Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report (Businesswire)
26.05.21	Aptorum Group CEO Subscribed Shares In The Company (Businesswire)
24.05.21	Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma (Businesswire)
13.05.21	Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference (Businesswire)
06.05.21	Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions (Businesswire)
23.04.21	Aptorum Group Limited Interview to Air on Bloomberg Television U.S. on the RedChip Money Report (Businesswire)
22.04.21	Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases (Businesswire)
19.04.21	Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update (Businesswire)
20.01.21	Stock Alert: Aptorum Up 30% On Clearance To Initiate Phase 1 Trial Of ALS-4 In Canada (RTTNews)
07.12.20	Pre-market Movers In Healthcare Sector: OBLN, EYES, CYAD, ONCT, BCRX… (RTTNews)
30.10.20	Pre-market Movers In Healthcare Sector: MGEN, EQ, SNSS, IPHA, BLCM, AXGT… (RTTNews)
29.10.20	Pre-market Movers In Healthcare Sector: VSTM, APM, KALA, BNTX, CGIX... (RTTNews)
16.10.20	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020 (Businesswire)
02.10.20	Aptorum Group Announces Closing of $9.0 Million Public Offering (Businesswire)
01.10.20	SELB Down But Not Out, PFE Takes 9.9% Stake In CStone, ZSAN Plunges, AMAG On The Block? (RTTNews)
30.09.20	Aptorum Group Announces Pricing of $9.0 Million Public Offering (Businesswire)
08.09.20	Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10 (Businesswire)
08.09.20	Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance (Businesswire)
03.09.20	AGTC Abuzz, AMRN Slumps & CORT Soars As Oral Arguments Commence, FLGT Gears Up, NNVC On Watch (RTTNews)
02.09.20	Aptorum Group Announces Video Update Discussing Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types (Businesswire)
01.09.20	Pre-market Movers In Healthcare Sector: APM, TTOO, BCRX, ZSAN, BNTX... (RTTNews)
01.09.20	Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types (Businesswire)
01.09.20	Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	610.40	2.14 %	K V
Logitech Intl	89.10	0.54 %	K V
Alcon	83.04	0.14 %	K V
Zurich Insur Gr	554.00	0.14 %	K V
Part Grp Hldg	1’380.00	0.07 %	K V
Nestle	77.52	-0.44 %	K V
Kuehne+Nagel Int	202.30	-0.44 %	K V
Swisscom	506.50	-0.69 %	K V
Sonova Hldg	308.40	-2.41 %	K V
UBS Group	30.19	-5.03 %	K V

Nachrichten zu Aptorum Group Ltd Registered Shs -A-

Aktien Top/Flop

Meistgelesene Nachrichten